TY - JOUR
T1 - Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins
AU - Guerrero-Muñoz, M.J.
AU - Castillo-Carranza, D.L.
AU - Kayed, R.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2014/4/15
Y1 - 2014/4/15
N2 - Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.
AB - Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.
UR - http://www.scopus.com/inward/record.url?scp=84897954120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897954120&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2013.12.023
DO - 10.1016/j.bcp.2013.12.023
M3 - Review article
SN - 0006-2952
VL - 88
SP - 468
EP - 478
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 4
ER -